Age-Related Macular Degeneration (AMD)
- Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions
- Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular Degeneration: The Phase 2 CANDELA Randomized Clinical Trial
- Port delivery system with ranibizumab (Susvimo) recall: What does it mean to the retina specialists
- Comprehensive Preclinical Assessment of ADVM-022, an Intravitreal Anti-VEGF Gene Therapy for the Treatment of Neovascular AMD and Diabetic Macular Edema
- Suprachoroidal Delivery of RGX-314 Well-Tolerated in Wet AMD
- FDA approves faricimab for treatment of wet AMD, DME
- TENAYA and LUCERNE: Rationale and Design for the Phase 3 Clinical Trials of Faricimab for Neovascular Age-Related Macular Degeneration
- Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials
- YOSEMITE and RHINE Phase 3 Randomized Clinical Trials of Faricimab for Diabetic Macular Edema: Study Design and Rationale
- Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials
- Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration
- Port delivery system: a novel drug delivery platform to treat retinal diseases
- Review of gene therapies for age-related macular degeneration.
- Treat-and-Extend Therapy Using Aflibercept for Neovascular Age-related Macular Degeneration: A Prospective Clinical Trial
- Efficacy and safety of intravitreal aflibercept using a treat-and-extend regimen for neovascular age-related macular degeneration: The ARIES Study: A Randomized Clinical Trial
- Treat-and-Extend versus Monthly Regimen in Neovascular Age-Related Macular Degeneration: Results with Ranibizumab from the TREND Study
- Efficacy of a Treat-and-Extend Regimen With Ranibizumab in Patients With Neovascular Age-Related Macular Disease
- The Potential Importance of Detection of Neovascular Age-Related Macular Degeneration When Visual Acuity Is Relatively Good
- Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration
- Vision Outcomes Following Anti-Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema in Clinical Practice
- Faricimab shows efficacy, safety and durability in treatment of wet AMD
- Management and Outcomes for Neovascular Age-Related Macular Degeneration: Analysis of United States Electronic Health Records
- Impact of intravitreal aflibercept dosing regimens in treatment-naïve patients with neovascular age-related macular degeneration: 2-year results of RAINBOW
- Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies
- Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR
- Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Randomized Clinical Trial
- Effect of Intravitreous Anti–Vascular Endothelial Growth Factor vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic Retinopathy: The Protocol W Randomized Clinical Trial
- End of Study Results for the Ladder Phase 2 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration
- Gene therapy for neovascular age-related macular degeneration: rationale, clinical trials and future directions
- Efficacy and Safety of Abicipar in Neovascular Age-Related Macular Degeneration
- Abicipar pegol—a novel anti-VEGF therapy with a long duration of action
- Port Delivery System With Ranibizumab Shows Positive Phase III Results in Neovascular Age-Related Macular Degeneration
- Use and Safety of brolucizumab
- Intravitreal Aflibercept for AMD: 2-year Results
- What AREDS means for you?
- Addressing the Anti-VEGF Treatment Burden
- ICD-10 Decision Tree: AMD
- Mayo Clinic: Dry Macular Degeneration
- American Academy of Ophthalmology Preferred Practice Patterns for AMD
- Understanding Your AMD – Patient Handout
- Protecting Eye Health and Possibly Reducing Risk for Developing Macular Degeneration – Patient Handout
- Research progress about the effect and prevention of blue light on eyes
- The Good and Bad of Retinal Fluid
- Review of Neovascular Age-Related Macular Degeneration Treatment Options
- Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: a comparative review.
- Results from the Randomized Phase 2 Ladder Clinical Trial
- Results from the Phase 3 HAWK and HARRIER Studies
- Faricimab Demonstrates Durable Ang-2, VEGF Suppression
- Age-Related Macular Degeneration (AMD) Data and Statistics – Patient Education
- Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration
Cataract and/or Refractive Surgery
- AAO Refractive Surgery Preferred Practice Patterns 2022
- Biometry in cataract surgery: a review of the current literature
- Saving of Time Using a Software-Based versus a Manual Workflow for Toric Intraocular Lens Calculation and Implantation
- Comparison of cumulative dissipated energy delivered by active-fluidic pressure control phacoemulsification system versus gravity-fluidics
- Application of artificial intelligence in cataract management: current and future directions
- Improving accuracy for intraocular lens selection in cataract surgery
- Latest Development in Extended Depth-of-Focus Intraocular Lenses: An Update
- AAO Cataract in the Adult Eye Preferred Practice Pattern 2021
- Intraoperative and postoperative pain in cataract surgery
- Dexamethasone Intracameral Drug-Delivery Suspension for Inflammation Associated with Cataract Surgery
- Does Cataract Surgery Hurt?
- Strategies for Preventing Intraoperative Miosis
- Cataract and Refractive Lens Exchange Questionnaire
- Post-Refractive IOL Calculator
- American Academy of Ophthalmology Task Force Consensus Statement for Extended Depth of Focus Intraocular Lenses
- American Society of Cataract and Refractive Surgery
- Physician Quality Reporting System Measures Associated with Cataract Surgery
- Toric IOL Calculator
- Preparing for Cataract Surgery – Postoperative Concerns – Patient Handout
- Multicenter randomized phase 3 study of a sustained-release intracanalicular dexamethasone insert for treatment of ocular inflammation and pain after cataract surgery
Conjunctivitis
- Conjunctivitis (Pink Eye) Treatment
- Conjunctivitis: What is Pink Eye? – Patient Information
- Help Protect Yourself From Getting & Spreading Pink Eye (Conjunctivitis) – Patient Handout
Diabetic Macular Edema (DME)
- KESTREL and KITE Phase 3 studies: 100-week results with brolucizumab in patients with diabetic macular edema
- Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial
- Shall we stay, or shall we switch? Continued anti-VEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edema
- Two-year interim safety results of the 0.2 µg/day fluocinolone acetonide intravitreal implant for the treatment of diabetic macular oedema: the observational PALADIN study
- The USER Study: A Chart Review of Patients Receiving a 0.2 µg/day Fluocinolone Acetonide Implant for Diabetic Macular Edema
- A Collaborative Retrospective Study on the Efficacy and Safety of Intravitreal Dexamethasone Implant in Patients with Diabetic Macular Edema: The European DME Registry Study
- Aqueous Cytokine Expression and Higher Order OCT Biomarkers: Assessment of the Anatomic-Biologic Bridge in the IMAGINE DME Study
- Anatomic Response to Intravitreal Dexamethasone Implant and Baseline Aqueous Humor Cytokine Levels in Diabetic Macular Edema
- Study of 27 Aqueous Humor Cytokines in Type 2 Diabetic Patients with or without Macular Edema
- The Mechanism of the Bispecific Antibody Faricimab
- Differential response to intravitreal dexamethasone implant in naïve and previously treated diabetic macular edema eyes
- Understanding How Diabetes Can Affect Your Vision and Cause Diabetic Macular Edema – Patient Handout
- American Optometric Association Evidence-Based Clinical Practice Guideline: Eye Care of the Patient with Diabetes Mellitus
- Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-year Results from a Comparative Effectiveness Randomized Clinical Trial
- Facts About Macular Edema
- 5 Year Outcomes After Aflibercept, Bevacizumab, or Ranibizumab for DME: Protocol T Extension Study
- Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With Diabetic Macular Edema Involving the Center of the Macula and Good Visual Acuity
- Assessment of the DRCR Retina Network Approach to Management With Initial Observation for Eyes With Center-Involved Diabetic Macular Edema and Good Visual Acuity: A Secondary Analysis of a Randomized Clinical Trial
- Treatment Patterns for Diabetic Macular Edema: An Intelligent Research in Sight (IRIS®) Registry Analysis
- Evaluation of Patients Receiving Intravitreal Antivascular Endothelial Growth Factor for Diabetic Macular Edema in Clinical Practice in the United States
Diabetic Retinopathy
- Diabetic Retinopathy: Are You Being Screened? (for Patients)
- Retina Summary Benchmarks, 2021 (for Patients)
- What Is Diabetic Retinopathy?
- Understanding Diabetic Retinopathy – Patient Handout
- Diabetic Retinopathy Clinical Research Network Publications
- Diabetic Retinopathy: Causes, Symptoms, Treatment
- ICD-10 Decision Tree: Diabetes
- Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy
- Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial
- Early intervention with Aflibercept has positive results in PANORAMA trial
- Digital Algorithmic Diabetic Retinopathy Severity Scoring System (An American Ophthalmological Society Thesis)
- Early intervention with Afilbercept has positive results in PANORAMA trial
- What’s Next for Bispecific Antibody Faricimab
- PANORAMA: Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy
- Protocol W: Effect of Intravitreous Anti–Vascular Endothelial Growth Factor vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic Retinopathy
- Risk of Blindness Among Patients With Diabetes and Newly Diagnosed Diabetic Retinopathy
- Comparison of Early Treatment Diabetic Retinopathy Study Standard 7-Field Imaging With Ultrawide-Field Imaging for Determining Severity of Diabetic Retinopathy
Geographic Atrophy
- Understanding Geographic Atrophy in Advanced Non-Exudative Age-Related Macular Degeneration: a Teaching Case Report
- Seeing Beyond Anatomy: Quality of Life with Geographic Atrophy
- Patient Perspectives in Geographic Atrophy (GA): Exploratory Qualitative Research to Understand the Impact of GA for Patients and Their Families
- Seeing Beyond Anatomy: Quality of Life with Geographic Atrophy
- Clinically relevant deep learning for detection and quantification of geographic atrophy from optical coherence tomography: a model development and external validation study
- Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial
- C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration
- Prevalence and phenotype associations of complement factor I mutations in geographic atrophy
- Natural History of Geographic Atrophy Secondary to Age-Related Macular Degeneration
- Pegcetacoplan treatment for geographic atrophy due to age-related macular degeneration: a plain language summary of the FILLY study
- Predicting Topographic Disease Progression and Treatment Response of Pegcetacoplan in Geographic Atrophy Quantified by Deep Learning
- Color Vision and Microperimetry Changes in Nonexudative Age-Related Macular Degeneration After Risuteganib Treatment: Exploratory Endpoints in a Multicenter Phase 2a Double-Masked, Randomized, Sham-Controlled, Crossover Clinical Trial
General
- ICD-10-CM for Ophthalmology
- EyeNet Magazine
- National Institutes of Health Guidelines on Human Subjects Research
- Eye Health Tips – Patient Handout
- AAO Preferred Practice Patterns
- American Academy of Ophthalmology. Teleophthalmology: how to get started.
- Centers for Medicare and Medicaid Services. Medicare telemedicine health care provider fact sheet.
- Vicchrilli S. Savvy coder: telemedicine during the public health emergency.
- AAO.org: Home Eye Test for Adults
Glaucoma
- CDC Vision Health Initiative: Facts About Glaucoma
- ICD-10 Glaucoma Reference Guide
- Bimatoprost Implant Biodegradation in the Phase 3, Randomized, 20-Month ARTEMIS Studies
- The effectiveness and safety profile of netarsudil 0.02% in glaucoma treatment: real-world 6-month outcomes
- A multicenter, open-label study of netarsudil for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension in a real-world setting
- Real-World Clinical Impact of Netarsudil 0.02% at an Urban Safety-Net Hospital
- National Eye Institute: Glaucoma
- Advances in medical therapy for glaucoma
- New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost
- Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2
- Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis
- 2 Year Experience with Latanoprostene Bunod in Clinical Practice
- Sustained-release drug delivery systems for the treatment of glaucoma
- Investigational Rho Kinase Inhibitors for the Treatment of Glaucoma
- Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study
- A multicenter, open-label study of netarsudil for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension in a real-world setting
- Real-World Clinical Impact of Netarsudil 0.02% at an Urban Safety-Net Hospital
- Advances in medical therapy for glaucoma
- New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost
- Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2
- Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis
- 2 Year Experience with Latanoprostene Bunod in Clinical Practice
- Latanoprostene Bunod 0.024% in Subjects With Open-angle Glaucoma or Ocular Hypertension: Pooled Phase 3 Study Findings
- Prospective Study of NCX 470 for IOP Lowering: Phase 2 Clinical Results
- Advances in medical therapy for glaucoma
- New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost
- Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2
- Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis
- Phase 3, Randomized, 20-Month Study of Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1)
- Bimatoprost Implant. Prescribing Information
- Netarsudil and Latanoprost Ophthalmic Solution Prescribing Information
- A Review of Nitric Oxide for the Treatment of Glaucomatous Disease
- Surgical Innovations in Glaucoma
- Microinvasive Glaucoma Surgery (MIGS)
- Xen Gel Stent: Directions for Use
- Netarsudil Prescribing Information
- Latanoprostene Bunod Prescribing Information
- American Glaucoma Society
- Don’t Lose Sight of Glaucoma – Patient Handout
- What You Need to Know About Glaucoma – Patient Handout
- ICD-10 Glaucoma Reference Guide
- Facts About Glaucoma
Inherited Retinal Diseases
- Advancing Clinical Trials for Inherited Retinal Diseases: Recommendations from the Second Monaciano Symposium
- Genetic testing and diagnosis of inherited retinal diseases
- Adeno-Associated Viral Gene Therapy for Inherited Retinal Disease
- AAO Guidelines on Clinical Assessment of Patients with Inherited Retinal Degenerations – 2022
- Genetic Testing for Inherited Retinal Disease
- Gene therapy for the treatment of X-linked retinitis pigmentosa
- Genetic testing for inherited retinal degenerations: Triumphs and tribulations
- Patient Information – Inherited Retinal Diseases
- Foundation Fighting Blindness
Macular Disorders
- Management Recommendations for Macular Hole
- Revised Definitions from the International Classification of Diseases of the Vitreomacular Interface
- Understanding Vitreomacular Traction Syndrome – Patient Handout
- Managing Challenging Macular Holes
Neurotrophic Keratitis
- Cenegermin Prescribing Information
- Phase II Randomized, Double-Masked, Vehicle-Controlled Trial of Recombinant Human Nerve Growth Factor for Neurotrophic Keratitis
- Phase IV Multicenter, Prospective, Open-Label Clinical Trial of Cenegermin (rhNGF) for Stage 1 Neurotrophic Keratopathy (DEFENDO)
- Neurotrophic keratopathy: An updated understanding
- Long-term clinical efficacy of topical treatment with recombinant human nerve growth factor in neurotrophic keratopathy: a novel cure for a rare degenerative corneal disease?
- Topical human recombinant nerve growth factor for stage 1 Neurotrophic Keratitis: Retrospective case series of cenegermin treatment.
- Neurotrophic Keratitis: Early Intervention is Key
- Topical Recombinant Human Nerve Growth Factor (Cenegermin) for Neurotrophic Keratopathy
- Amniotic membrane transplantation for managing dry eye and neurotrophic keratitis
- Neurotrophic keratopathy: current challenges and future prospects
- Expert consensus on the identification, diagnosis, and treatment of neurotrophic keratopathy
- Diagnosis and management of neurotrophic keratitis
- Cenegermin: A Review in Neurotrophic Keratitis
Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis
- International Delphi Consensus on the Management of AQP4-IgG+ NMOSD. Recommendations for Eculizumab, Inebilizumab, and Satralizumab
- Contemporary management challenges in seropositive NMOSD
- Guthy Jackson Foundation
- Impact of Neuromyelitis Optica Spectrum Disorder on Quality of Life from the Patients’ Perspective: An Observational Cross-Sectional Study
- Pain, Depression, and Quality of Life in Neuromyelitis Optica Spectrum Disorder
- AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in NMOSD
- Long-term efficacy and safety of inebilizumab in NMOSD: Analysis of AQP4-IgG seropositive participants taking inebilizumab for ⩾4 years in the N-MOmentum trial
- Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder
- Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum)
- Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder (SAkuraStar)
- International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
- Neuromyelitis Optica Spectrum Disorder
- The Sumaira Foundation for NMO
- Eculizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder
- Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder
Ocular Surface and Lid Margin Disease
- Dysfunctional Tear Syndrome: Dry Eye Disease and Associated Tear Film Disorders
- Meibomian gland disease: the role of gland dysfunction in dry eye disease
- A Randomized Clinical Study (SEECASE) to Assess Efficacy, Safety, and Tolerability of NOV03 for Treatment of Dry Eye Disease
- Efficacy of NOV03 (Perfluorohexyloctane) on Signs and Symptoms of Dry Eye Disease associated with Meibomian Gland Dysfunction: The Mojave study
- Optimization of the Ocular Surface Through Treatment of Ocular Surface Disease Before Ophthalmic Surgery: A Narrative Review
- Racial and Ethnic Disparities in Dry Eye Diagnosis and Care
- Efficacy of the Systane iLux Thermal Pulsation System for the Treatment of Meibomian Gland Dysfunction After 1 Week and 1 Month: A Prospective Study
- Comparison of Two Thermal Pulsation Systems in the Treatment of Meibomian Gland Dysfunction: A Randomized, Multicenter Study
- Practical Guidance for the Use of Loteprednol Etabonate Ophthalmic Suspension 0.25% in the Management of Dry Eye Disease
- Selective Pharmacologic Therapies for Dry Eye Disease Treatment: Efficacy, Tolerability, and Safety Data Review from Preclinical Studies and Pivotal Trials
- AAO EyeWiki: Meibomian Gland Dysfunction (MGD)
- NIH Dry Eye Patient Information
- Tear film thickness after treatment with artificial tears in patients with moderate dry eye disease
- Meibomian gland disease: the role of gland dysfunction in dry eye disease
- A Randomized Clinical Study (SEECASE) to Assess Efficacy, Safety, and Tolerability of NOV03 for Treatment of Dry Eye Disease
- Efficacy of NOV03 (Perfluorohexyloctane) on Signs and Symptoms of Dry Eye Disease associated with Meibomian Gland Dysfunction: The Mojave study
- Effect of Hyaluronic Acid/Trehalose in Two Different Formulations on Signs and Symptoms in Patients with Moderate to Severe Dry Eye Disease
- Lotilaner Ophthalmic Solution, 0.25%, for the Treatment of Demodex Blepharitis: Results of a Prospective, Randomized, Vehicle-Controlled, Double-Masked, Pivotal Trial (Saturn-1)
- Demodex Blepharitis: Clinical Perspectives
- Demodex and Eye Disease
- A Clinical Scoring System for Diagnosis of Ocular Demodicosis
- Efficacy and Safety of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease: The ONSET-2 Phase 3 Randomized Trial
- A phase II randomized trial to evaluate the long-term (12-week) efficacy and safety of OC-01 (varenicline solution) nasal spray for dry eye disease: The MYSTIC study
- Emerging therapies for dry eye disease
- AAO: Improved Dry Eye Drugs for 2022 and Beyond
- The role of KPI-121 0.25% in the treatment of dry eye disease: penetrating the mucus barrier to treat periodic flares
- New strategies for the management of ocular surface disease in glaucoma patients
- Phase 3 Efficacy (Worse-Eye Analysis) and Long-Term Safety Evaluation of OTX-101 in Patients with Keratoconjunctivitis Sicca
- Efficacy and Safety of OTX-101, a Novel Nanomicellar Formulation of Cyclosporine A, for the Treatment of Keratoconjunctivitis Sicca: Pooled Analysis of a Phase 2b/3 and Phase 3 Study
- Safety of KPI-121 Ophthalmic Suspension 0.25% in Patients With Dry Eye Disease: A Pooled Analysis of 4 Multicenter, Randomized, Vehicle-Controlled Studies
- Neurostimulation in dry eye disease-past, present, and future
- Comparison of the iLUX and the LipiFlow for the Treatment of Meibomian Gland Dysfunction and Symptoms: A Randomized Clinical Trial
- Dupilumab-associated ocular surface disease: presentation, management and long-term sequelae
- A Clinician’s Guide to the Recognition and Management of Dupilumab-Associated Conjunctivitis
- Diseases of Ocular Surface
- Dry Eye: Patient Information
- TFOS DEWS II Definition and Classification Report
- American Academy of Ophthalmology Preferred Practice Patterns: Dry Eye Syndrome
- Care of the Patient with Ocular Surface Disorders
- American Academy of Ophthalmology Preferred Practice Patterns: Blepharitis
- Sjögren’s Syndrome Foundation
Presbyopia
- Living with presbyopia: experiences from a virtual roundtable dialogue among impacted individuals and healthcare professionals
- In Vitro and In-Eye Comparison of Commercial Pilocarpine Ophthalmic Solution and an Optimized, Reformulated Pilocarpine for Presbyopia Treatment
- Review of Presbyopia Treatment with Corneal Inlays and New Developments
- Safety and Efficacy of AGN-190584 in Individuals With Presbyopia The GEMINI 1 Phase 3 Randomized Clinical Trial
- 1.25% Pilocarpine for Presbyopia
- Potential new presbyopia treatments in development
- What Is Presbyopia? (Patient Material)
- Presbyopia Treatment (Patient Material)
- A Review of Pharmacological Presbyopia Treatment
- Treatments for presbyopia coming soon
Retinal Vascular Diseases (RVO)
- Wide-field angiography in retinal vein occlusions
- Peripheral retinal non-perfusion and treatment response in branch retinal vein occlusion
- Association of Disorganization of Retinal Inner Layers With Visual Acuity Response to Anti–Vascular Endothelial Growth Factor Therapy for Macular Edema Secondary to Retinal Vein Occlusion
- Relationship Between Nerve Fiber Layer Hemorrhages and Outcomes in Central Retinal Vein Occlusion
- Clinical Effectiveness of Intravitreal Therapy With Ranibizumab vs Aflibercept vs Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion: A Randomized Clinical Trial
- Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend for Macular Edema in Central Retinal Vein Occlusion: the CENTERA Study
- Visual acuity outcomes and anti-VEGF therapy intensity in macular oedema due to retinal vein occlusion: a real-world analysis of 15 613 patient eyes
- Real world evidence on 5661 patients treated for macular oedema secondary to branch retinal vein occlusion with intravitreal anti-vascular endothelial growth factor, intravitreal dexamethasone or macular laser
- Five-year outcomes of retinal veinocclusion treated with vascularendothelial growth factor inhibitors
- Twelve-month outcomes of ranibizumab versus aflibercept for macular oedema in branch retinal vein occlusion: data from the FRB! registry
- Branch Retinal Vein Occlusion Information for Patients
- Central Retinal Vein Occlusion Information for Patients
- ICD-10 Decision Tree: Vein Occlusion
- Understanding Your Retinal Vein Occlusion (RVO) – Patient Handout
- Retinal Vein Occlusions Preferred Practice Patterns
Thyroid Eye Disease (TED)
- Thyroid Eye Disease: Navigating Diagnosis and Treatment
- Patient Brochures
- Navigating the New Treatment Landscape
- Graves’ Eye Disease: Patient Information from the American Thyroid Association
- Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment OPTIC-X Study
- Future Projections in Thyroid Eye Disease
- Patient Material: Examining the Optics of TED
- Teprotumumab and the Evolving Therapeutic Landscape in Thyroid Eye Disease
- Therapeutic IGF-I receptor inhibition alters fibrocyteimmune phenotype in thyroid-associated ophthalmopathy
- Hearing Dysfunction After Treatment with Teprotumumab for Thyroid Eye Disease
- Teprotumumab for patients with active thyroid eye disease: pooled data analysis, subgroup analyses, andoff-treatment follow-up results
- Thyroid Eye Disease, Teprotumumab, and Hearing Loss: An Evolving Role for Otolaryngologists
- Audiology findings in patients with teprotumumab associated otologic symptoms
- Graves’ Ophthalmopathy
- Review Article: Graves’ Disease
- Graves’ Disease: Patient Information
- Teprotumumab for the Treatment of Active Thyroid Eye Disease
Uveitis
- Efficacy and Safety of Suprachoroidal CLS-TA for Macular Edema Secondary to Noninfectious Uveitis: Phase 3 Randomized Trial (PEACHTREE)
- Real-Life Efficacy, Safety, and Use of Dexamethasone Intravitreal Implant in Posterior Segment Inflammation Due to Non-infectious Uveitis (LOUVRE 2 Study)
- Epidemiology and Risk Factors in Non-infectious Uveitis: A Systematic Review
- Periocular Triamcinolone vs. Intravitreal Triamcinolone vs. Intravitreal Dexamethasone Implant for the Treatment of Uveitic Macular Edema: The PeriOcular vs. INTravitreal corticosteroids for uveitic macular edema (POINT) Trial
- OCT Anatomic and Temporal Biomarkers in Uveitic Macular Edema
- Visual Acuity in Retinal Vein Occlusion, Diabetic, and Uveitic Macular Edema: Central Subfield Thickness and Ellipsoid Zone Analysis
- Fluocinolone Acetonide Intravitreal Implant for Treating Recurrent Non-infectious Uveitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
- Preparing for Your Appointment – Patient Handout
- Uveitis Guidelines: Immunomodulatory Therapy
- Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis
- MUST Study 7-Year Results
- Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL III
